Lake Street Capital Markets Analyst, Frank Takkinen, initiated coverage of CVRx, Inc. with a BUY rating and price target of $20 (CVRX-$20). CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases.
None of the information contained in this website constitutes a recommendation, solicitation or offer by Lake Street Capital Markets or its affiliates to buy or sell any securities, options or other financial instruments or provide any investment advice or service. Certain transactions give rise to substantial risk and are not suitable for all investors. Past performance does not guarantee future results.
920 Second Avenue South
Suite 700
Minneapolis, MN 55402
Copyright © 2020 Lake Street Capital Markets
